<--- Back to Details
First PageDocument Content
Health / Biotechnology / Patent law / Research exemption / Generic drug / Food and Drug Administration / Abbreviated New Drug Application / Drug Price Competition and Patent Term Restoration Act / Declaratory judgment / Approved Drug Products with Therapeutic Equivalence Evaluations / Novartis
Date: 2014-04-13 16:08:55
Health
Biotechnology
Patent law
Research exemption
Generic drug
Food and Drug Administration
Abbreviated New Drug Application
Drug Price Competition and Patent Term Restoration Act
Declaratory judgment
Approved Drug Products with Therapeutic Equivalence Evaluations
Novartis

Microsoft Word - 10CV5118 Seattle Childrens Hosp v Akorn MTD.doc

Add to Reading List

Source URL: orangebookblog.typepad.com

Download Document from Source Website

File Size: 75,90 KB

Share Document on Facebook

Similar Documents

Aquis Exchange Monthly Statistics May-2016 € 6,758,607,,245,455  Novartis AG

Aquis Exchange Monthly Statistics May-2016 € 6,758,607,,245,455 Novartis AG

DocID: 1xVO3 - View Document

Aquis Exchange Monthly Statistics Dec-2015 € 4,614,167,,256,050  Novartis AG

Aquis Exchange Monthly Statistics Dec-2015 € 4,614,167,,256,050 Novartis AG

DocID: 1xVKG - View Document

Aquis Exchange Monthly Statistics Apr-2016 € 7,708,388,,903,457  Novartis AG

Aquis Exchange Monthly Statistics Apr-2016 € 7,708,388,,903,457 Novartis AG

DocID: 1xTdg - View Document

PDF Document

DocID: 1xJ9t - View Document

PDF Document

DocID: 1xzSc - View Document